Evofem Biosciences to Report Third Quarter 2020 Results and Provide Corporate Update on Monday, November 9, 2020

Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on November 9, 2020, at 5:00 p.m. ET to discuss its third quarter 2020 financial results and business highlights. Interested parties can access the live webcast and related presentation on the Company's Investor page. Dial-in numbers for participation include (866) 503-5561 (U.S. toll-free) and (253) 336-2965. A telephone replay will be available shortly after the call through November 12, 2020, using conference ID 2639368.

SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the third quarter ended September 30, 2020 as follows:

Date	Monday, November 9, 2020
Time	5:00 p.m. ET (2:00 p.m. PT)
Webcast (live and archived)	www.evofem.com under "Investors"
Dial-in numbers	(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Conference ID	2639368

The live webcast and related slide presentation can be accessed on the Company's Investor page at https://evofem.investorroom.com/events or directly at https://edge.media-server.com/mmc/p/e4ij5fy8.  Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required.

If participating by phone, please dial in approximately 15 minutes prior to the start of the call.

A telephone replay will be available approximately two hours after the call through Thursday, November 12, 2020 at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 2639368. The webcast will be archived at https://evofem.investorroom.com/events.

About Evofem Biosciences, Inc.

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com.

Phexxi™ is a trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Media Contact
Ellen Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com 
Mobile: (718) 490-3248

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-third-quarter-2020-results-and-provide-corporate-update-on-monday-november-9-2020-301160339.html

SOURCE Evofem Biosciences, Inc.

FAQ

When is Evofem Biosciences' third quarter 2020 earnings call?

Evofem Biosciences will hold its third quarter 2020 earnings call on November 9, 2020, at 5:00 p.m. ET.

How can I access Evofem Biosciences' Q3 2020 webcast?

The Q3 2020 webcast can be accessed on Evofem's Investor page at www.evofem.com under 'Investors'.

What are the dial-in numbers for the Evofem call?

The dial-in numbers for the Evofem call are (866) 503-5561 for U.S. participants and (253) 336-2965 for international participants.

Will there be a replay of the Evofem earnings call?

Yes, a telephone replay of the Evofem earnings call will be available until November 12, 2020, using the conference ID 2639368.

What is Evofem Biosciences known for?

Evofem Biosciences focuses on women's sexual and reproductive health, known for its product Phexxi™, a hormone-free contraceptive.